Truist analyst Srikripa Devarakonda raised the firm’s price target on Eli Lilly to $1,033 from $1,000 and keeps a Buy rating on the shares. The firm is adjusting the In-Process Research and Development – IPR&D – expense in its model ahead of the company’s Q3 results, the analyst tells investors in a research note. Truist is also updating its ramp expectations for Zepbound while keeping its peak penetration and peak sales assumption at about $30B, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- On drug prices, Harris pushes for cuts, Trump offers few specifics, NYTimes say
- LLY, NVS, or ISRG: Which Healthcare Stock Scores Wall Street’s “Strong Buy” Rating?
- CBO sees medicare covering anti-obesity drugs raising federal spending by $35B
- PepsiCo reports mixed Q3, Roblox slips after short report: Morning Buzz
- Eli Lilly sees $3.08 per share in acquired IPR&D charges in Q3